Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma
N Engl J Med
.
2018 Apr 19;378(16):1560-1561.
doi: 10.1056/NEJMc1802363.
Authors
Joseph M Connors
1
,
John A Radford
2
Affiliations
1
British Columbia Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada jconnors@bccancer.bc.ca
2
University of Manchester, Manchester, United Kingdom
PMID:
29669231
DOI:
10.1056/NEJMc1802363
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Brentuximab Vedotin
Hodgkin Disease*
Humans
Immunoconjugates*
Substances
Antineoplastic Agents
Immunoconjugates
Brentuximab Vedotin